Practice change in the management of metastatic urothelial carcinoma after ASCO 2020

Pablo Gajate, Javier Torres-Jiménez, Carolina Bueno-Bravo, Felipe Couñago

Abstract
Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing the therapeutic landscape of mUC. Immune checkpoint inhibitors (ICIs) and targeted agents are useful treatment strategies that have been incorporated into our clinical practice. Nevertheless, cisplatin-based chemotherapy is still the standard of care in the first-line of metastatic disease. The results of the JAVELIN Bladder 100 phase 3 trial were presented at ASCO 2020, this trial evaluated the role of avelumab, an ICI, as maintenance therapy in patients who had not progressed after first-line platinum-based chemotherapy. The trial met its primary endpoint demonstrating an overall survival benefit with avelumab maintenance. In addition, new drugs and combinations are being evaluated to improve the outcomes of second and subsequent lines. Fibroblast growth factor receptor (FGFR) inhibitors and immunotherapy combinations were some of the strategies presented at ASCO 2020 that have shown promising results. Finally, the development of predictive biomarkers that help us in the decision-making process will be one of the most important challenges in the next years.

Key Words: Metastatic urothelial carcinoma; Immune checkpoint inhibitors; Avelumab; JAVELIN Bladder 100; FGFR inhibitors; ASCO 2020

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
**Core Tip:** The landscape of urothelial carcinoma treatment has changed significantly in the last 5 years. Several drugs with different mechanisms of action have emerged as new therapeutic opportunities. At ASCO 2020, avelumab, an immune checkpoint inhibitor, was evaluated as maintenance therapy in the JAVELIN Bladder 100 trial: This was the first clinical trial that improved overall survival in the metastatic setting since the 80s. Moreover, new drugs and combination strategies have shown their potential role as new therapeutic alternatives to increase survival in this disease which has a poor prognosis.

**Citation:** Gajate P, Torres-Jiménez J, Bueno-Bravo C, Couñago F. Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. *World J Clin Oncol* 2020; 11(12): 976-982
URL: https://www.wjgnet.com/2218-4333/full/v11/i12/976.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i12.976

**INTRODUCTION**

Bladder cancer is the 10th most common cancer worldwide with an estimated 550000 new cases and 200000 deaths in 2018[1]. Urothelial carcinoma is the predominant histologic type, with approximately 90% of bladder cancers in the United States and Europe[2].

Cisplatin–based chemotherapy has been the standard of care first-line treatment for metastatic urothelial carcinoma (mUC) since 1980[3]. However, 50% of patients with mUC are ineligible for cisplatin treatment, and a carboplatin-based regimen is the standard chemotherapy alternative[4,5]. In addition, new drugs, such as immune checkpoint inhibitors (ICIs) and molecular targeted agents, have emerged as new therapeutic choices in the last 5 years and have changed the therapeutic landscape of mUC. ICI is a frontline option for PD-L1 positive metastatic tumors[6-8] and the standard treatment for second-line patients with disease progression after platinum-containing chemotherapy[9,10]. Furthermore, the Food and Drug Administration (FDA) has recently approved two targeted agents, erdafitinib and enfortumab vedotin, for patients with locally advanced or mUC who have previously received platinum-based chemotherapy[11,12].

At ASCO 2020, the JAVELIN Bladder 100 trial was presented as an attractive treatment strategy, which assessed an ICI as maintenance therapy after achieving an objective response or stable disease with first-line chemotherapy. New drugs and combination strategies have also shown their potential role as new therapeutic options to prolong survival in this disease which has a poor prognosis. Our objective is to summarize the most important studies in mUC that have just been presented at ASCO 2020, and how they modify the standard clinical practice.

**MOST RELEVANT STUDIES PRESENTED AT ASCO 2020**

JAVELIN Bladder 100 was one of the most important studies presented at ASCO 2020[13](Table 1). It is a randomized phase 3 trial, which assessed avelumab (anti-PD-L1 treatment) as maintenance therapy in patients with mUC whose disease had not progressed with first-line platinum-based chemotherapy. Seven hundred patients with unresectable or mUC were randomized 1:1 to receive avelumab (10 mg/kg intravenously every two weeks) and best supportive care (BSC) or BSC alone. Crossover was not allowed within the study. Patients had to achieve an objective response or stable disease after at least four cycles of gemcitabine and cisplatin or carboplatin. A maximum of 6 cycles were allowed. Patients were stratified by best response to first-line chemotherapy (complete/partial response vs stable disease) and localization of metastatic disease (visceral vs non-visceral). The co-primary endpoint was overall survival (OS) assessed from randomization in all patients and in the PD-L1 positive population. Progression-free survival (PFS), objective response rate (ORR) and safety were secondary endpoints. After a median follow-up of 19 mo avelumab plus BSC significantly prolonged OS vs BSC alone in the overall population [21.4 vs 14.3

---

**Specialty type:** Oncology  
**Country/Territory of origin:** Spain  
**Peer-review report’s scientific quality classification:** Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C  
Grade D (Fair): D  
Grade E (Poor): 0  
**Received:** July 2, 2020  
**Peer-review started:** July 2, 2020  
**First decision:** October 23, 2020  
**Revised:** November 1, 2020  
**Accepted:** November 11, 2020  
**Article in press:** November 11, 2020  
**Published online:** December 24, 2020  
**P-Reviewer:** Huo Q, Shomura M  
**S-Editor:** Huang P  
**L-Editor:** Webster JR  
**P-Editor:** Wang LL
**Table 1 Results of the most relevant studies at ASCO 2020**

| Study                | Phase  | Treatment                      | Inclusion criteria                                      | Study population (n) | PFS (mo)  | OS (mo)  | ORR (%) | Duration of response |
|----------------------|--------|--------------------------------|--------------------------------------------------------|----------------------|-----------|-----------|----------|----------------------|
| **JAVELIN Bladder 100**[13] | 1b/2   | Avelumab + BSC vs BSC          | Response or stable disease after 1st line platinum-based chemotherapy | 700                  | 3.7 vs 2.0 | 21.4 vs 14.3 | 9.7 vs 1.4 | NR                   |
| **FORT-2**[16]       | 1b     | Rogaratinib + atezolizumab     | Cisplatin ineligible                                    | 31                   | 101       | 40        | 44       | 5.98                 |
| **BLC2001**[14]      | 1b     | Erdafitinib                    | FGFR mRNA overexpression                               | 101                  | 5.52      | 11.3      | 40       | 5.98                 |
| **COSMIC-021**[18]   | 1b     | Cabozantinib + atezolizumab    | Prior ICI not allowed                                  | 30                   | 5.4       | 27        | 27       | NR                   |
| **PEANUT**[19]       | 2      | Pembrolizumab + nab-paclitaxel | Prior ICI not allowed                                  | 70                   | 5.0       | 38.6      | 38.6     | NR                   |

BSC: Best supportive care; ICI: Immune checkpoint inhibitor; FGFR: Fibroblast growth factor receptor; PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate.

Erdafitinib is a novel pan-fibroblast growth factor receptor (FGFR) kinase inhibitor recently approved by the FDA for patients with locally advanced or mUC with susceptible FGFR3 or FGFR2 genetic alterations who have progressed during or following platinum-based chemotherapy. Approval was based on data from the primary analysis of the BLC2001 study, a phase II trial that assessed erdafitinib in this group of patients[11]. The final results of this trial were presented at ASCO 2020, including long-term outcomes and safety data. With a median follow-up of 24 mo, the investigators confirmed an ORR of 40%, with a median duration of response of 6 mo. Furthermore, 31% of responders had a response duration of over 12 mo[14]. Median PFS was 5.52 mo and median OS was 11.3 mo. Central serous retinopathy (CSR) is a known class effect of FGFR inhibitors. CSR occurred in 27% (27/101) of patients, but 85% of those (23/27) were grade 1 or 2. In addition, a phase III trial is evaluating erdafitinib compared to pembrolizumab or chemotherapy in patients with mUC and FGFR alterations who have progressed after 1 or 2 prior treatments[13].

FORT-2 is a phase Ib/II study that evaluates the safety and efficacy of rogaratinib in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with mUC and FGFR mRNA overexpression[16]. Rogaratinib is a highly selective FGFR1-4 inhibitor that has shown good tolerability and clinical activity as monotherapy in a previous phase I trial[17]. Eleven patients were treated with rogaratinib 800 mg twice daily and atezolizumab 1200 mg every 3 wk, and 16 patients were treated with rogaratinib 600 mg twice daily and atezolizumab 1200 mg every 3 wk. The ORR was 44%, with a disease control rate of 68%. The duration of response was not reached. The safety profile was manageable with diarrhea (58%), hyperphosphatemia (45%) and urinary tract infection (36%) being the most common treatment-emergent adverse events.

The COSMIC-021 and PEANUT trials assessed the combination of an ICI with a targeted-agent or chemotherapy, respectively, in patients with mUC previously treated. COSMIC-021 is a multi-cohort phase 1b study that evaluates the immunomodulatory effect of cabozantinib (40 mg daily) in combination with
atezolizumab (1200 mg every 3 wk)\textsuperscript{18}. Thirty patients with mUC were included. The ORR was 27% including 2 patients with a complete response. The median duration of response was not reached. The median PFS was 5.4 mo. Asthenia (37%), diarrhea (27%), lower appetite (23%), increased transaminases (23%) and mucosal inflammation (20%) were the most frequent treatment-related adverse events (TRAEs). PEANUT is a phase 2 study evaluating the combination of pembrolizumab and nab-paclitaxel in patients previously treated with chemotherapy\textsuperscript{20}. Sixty-five patients were included. The median PFS was 5 mo, with an ORR of 38.6%. The median duration of response was not reached. This combination showed an expected safety profile with alopecia (71%), neutropenia (32%) and peripheral neuropathy (34%) as the most common TRAEs.

Finally, at ASCO 2020 the analysis of tumor microenvironment biomarkers from the IMvigor130 study was presented\textsuperscript{21}. This phase 3 trial compared atezolizumab with or without platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in the first-line treatment of mUC. The addition of atezolizumab to platinum-based chemotherapy prolonged PFS, which was one of the co-primary endpoints of the trial. In the biomarker analysis, clinical outcomes were evaluated by PD-L1 status, T-effector and TGF-\(\beta\)-response gene expression signature, tumor mutational burden and APOBEC mutation analysis. This exploratory analysis provided additional evidence for biomarkers previously associated with response and resistance to ICI.

**HOW WILL ASCO 2020 CHANGE CLINICAL PRACTICE IN MUC?**

Cisplatin-based chemotherapy is the standard first-line treatment for mUC. JAVELIN Bladder 100 met its primary endpoint, demonstrating significantly longer OS with first-line maintenance avelumab plus BSC compared to BSC alone, in both the overall and PD-L1 positive populations. In addition, all prespecified subgroups benefited from this treatment. According to these data, first-line maintenance avelumab should be offered in patients with mUC who achieved an objective response or stable disease with platinum-based chemotherapy. This includes approximately 85% of patients that start first-line platinum-based chemotherapy\textsuperscript{22}. Those with primary refractory disease (15%) should receive second-line treatment with ICIs. Nevertheless, only 25%-55% of patients that progress after first-line treatment receive new therapy\textsuperscript{23-25}. A maintenance strategy is a chance to increase the number of patients that will receive ICI therapy. In this context, there are other trials assessing the combination of ICI and chemotherapy in first-line treatment. The IMvigor130 study has recently been published\textsuperscript{26}. Its co-primary endpoints were PFS and OS. The combination of atezolizumab with platinum-based chemotherapy as first-line treatment prolonged PFS in patients with mUC. A statistically significant OS advantage was not observed in the interim analysis, however, these data are immature and a longer follow-up is needed. First-line maintenance avelumab in patients with mUC whose disease has not progressed with platinum-based chemotherapy should be considered a new standard of care.

Despite the approval of erdafitinib by the FDA, the European Medicines Agency (EMA) has not authorized it yet. The benefit from FGFR inhibitors in mUC patients with FGFR alterations has been demonstrated in different clinical trials. The long-term outcomes from the phase II erdafitinib study confirm the efficacy results observed in the interim analysis. In addition, new strategies are being evaluated such as combinations with other drugs and their role in prior lines or earlier stages. Although data from phase 3 trials are pending and some strategies are still under development, FGFR inhibitors will probably be included in the treatment algorithm of mUC in the near future.

ICI is the standard of care for the second-line treatment of mUC. Despite this, only a subset of patients responds to these therapies. The research for new strategies to increase the number of patients that benefit from ICI is one of the most important points in mUC management. In this direction, several clinical trials are assessing different combinations with promising results in phase II studies. Nevertheless, no randomized trials have shown superiority over ICI monotherapy. However, the probable position of immunotherapy in the first-line setting could modify these strategies.

PD-L1 expression in ineligible cisplatin patients is the only biomarker that has been integrated in clinical practice regarding ICI use in mUC\textsuperscript{27}. The development of biomarkers could be useful to identify patients who will benefit from the different treatment strategies, focusing on their potential predictive role rather than their solely
prognostic nature. Biomarkers associated with response and intrinsic resistance to ICIs have previously been identified in urothelial cancer. However, predictive biomarkers for combination regimens or maintenance therapy remain uncertain. It is necessary to integrate biomarker analysis in every clinical trial to identify patients who will benefit from each treatment strategy.

CONCLUSION

JAVELIN Bladder 100 was one of the most important studies presented at ASCO 2020. Avelumab maintenance treatment after first-line chemotherapy will change our standard of practice. Other clinical trials in this setting could offer new treatment strategies. Biomarker analysis should help us to identify the best treatment option in every single patient. Moreover, new drugs are being incorporated in the therapeutic landscape of mUC. The integration of all these treatment opportunities for our patients will be one of the most important challenges in mUC management.

REFERENCES

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, Epstein JJ, Reuter VE. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol 2013; 63: 16-35 [PMID: 23083804 DOI: 10.1016/j.eururo.2012.09.063]

3 Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii40-iii48 [PMID: 25096609 DOI: 10.1093/annonc/mdu223]

4 von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077 [PMID: 11001674 DOI: 10.1200/JCO.2000.18.17.3068]

5 De Santis M, Bellmunt J, Mead G, Kerst JM, Loahy M, Maroto P, Gil T, Marreau S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199 [PMID: 22162575 DOI: 10.1200/JCO.2011.37.3571]

6 Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist 2019; 24: 563-569 [PMID: 30541754 DOI: 10.1634/theoncologist.2018-0084]

7 Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bellmunt J, Mead G, Kerst JM, Leahy M, Marotto P, Gil T, Marreau S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer: a single-arm, multicentre, phase II study. Lancet 2017; 389: 65-76 [PMID: 27939400 DOI: 10.1016/S0140-6736(16)32455-2]

8 Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Atezolizumab maintenance in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 65-76 [PMID: 27939400 DOI: 10.1016/S0140-6736(16)32455-2]

9 Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Félignon T, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-757 [PMID: 29268948 DOI: 10.1016/S0140-6736(17)33297-X]

10 Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak
Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke

Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH,

Galsky MD

2018; Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.

Fisher MD

10 Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre.

Kotwal S, Prescott S, Henry A, Joseph J, Chilka S, Roulson JA, Weston M, Burbidge S, Brown S,

Galsky MD

Oncol

outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy

Bamias A, Mariathasan S. Tumor, immune, and stromal characteristics associated with clinical

Jin D, Koeppen H, Tayama D, Grande E, Arranz J, De Santis M, Davis ID, Kikuchi E, Shen X,

Galsky MD

10.1200/JCO.2020.38.15_suppl.5017

Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for

Giannatempo P

021 study.

Rosenberg JE

ClinicalTrials.gov Identifier: NCT03390504

N Engl J Med

Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. In: ClinicalTrials.gov

Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and

Janssen Research & Development; LLC Clinical Trials. A Study of Erdafitinib Compared With

Vergote I, Pal SK, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G.

Ligand 1 Therapy.

Mellado A, Bamias A, Mariathasan S, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De

Siefker-Radtke AO

DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y,

Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Cancer. N Engl J Med 2017; 376: 1015-1026 [PMID: 28212060 DOI: 10.1056/NEJMoai1613683]

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezzazedeh A, Melloado B, Varilamov S, Joshi M, Duran I, Tagawa ST, Zakaria Y, Zhong B, Stuckyenks K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; 381: 338-348 [PMID: 31340094 DOI: 10.1056/NEJMoai1817323]

Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Galsky MD

10.1200/JCO.2020.38.18_suppl.LBA1

BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020; 38: LBA1

[Schuler M, Cho BC, Sayehli CM, Naravaro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grelv J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20: 1454-1466 [PMID: 31405822 DOI: 10.1016/S1470-2045(19)30412-7]

Pal SK, Agarwal N, Loriot Y, Rodriguez CS, Singh P, Vaishampayan UN, Mcilvaine E, Curran D, Castellano D, Necchi A. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study. J Clin Oncol 2020; 38: 5014 [DOI: 10.1200/JCO.2020.38.15_suppl.5014]

Galsky MD, Bangchereau R, Hamidi HR, Leng N, Harris W, O'Donnell PH, Kadel EE, Yuen KCY, Jin D, Koeppen H, Tayama D, Grande E, Arranz J, De Santis M, Davis ID, Ikikuchi E, Shen X, Bamias A, Mariathasan S. Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) vs PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor103 study. J Clin Oncol 2020; 38: 5011 [DOI: 10.1200/JCO.2020.38.15_suppl.5011]

Galsky MD, Pal SK, Liu SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. Bladder Cancer 2018; 4: 227-238 [PMID: 29732393 DOI: 10.3233/BLC-170149]

Cheeseman S, Thompson M, Sowputh W, Godden P, Seshagiri D, Aledort L, Zucker K, Jain S, Kotsal S, Prescott S, Henry A, Joseph J, Chilka S, Rousslon JA, Weston M, Burbidge S, Brown S, Jagdev S, Ralph C, Hall G, Vasudev NS. Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre. Front Oncol 2020; 10 [DOI: 32154169 DOI: 10.3389/fonc.2020.00167]

Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS. Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015. Clin Genitourin Cancer 2018; 16: e1171-e117 [PMID: 30206026 DOI: 10.1016/j.clgc.2018.07.025]

Galsky MD, Aria JAA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Ozguroglu M, Kalebasty AR, Park SH, Aleskseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke
A, Thåström A, Grande E; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2020; 395: 1547-1557 [PMID: 32416780 DOI: 10.1016/S0140-6736(20)30230-0]
